SE307793B - - Google Patents

Info

Publication number
SE307793B
SE307793B SE4001/65A SE400165A SE307793B SE 307793 B SE307793 B SE 307793B SE 4001/65 A SE4001/65 A SE 4001/65A SE 400165 A SE400165 A SE 400165A SE 307793 B SE307793 B SE 307793B
Authority
SE
Sweden
Application number
SE4001/65A
Inventor
Douarec J Le
G Regnier
R Canevari
Original Assignee
Science Union & Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Science Union & Cie filed Critical Science Union & Cie
Publication of SE307793B publication Critical patent/SE307793B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
SE4001/65A 1964-04-22 1965-03-27 SE307793B (sl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB16696/64A GB1100281A (en) 1964-04-22 1964-04-22 New spiro-decane derivatives and process for the preparation thereof

Publications (1)

Publication Number Publication Date
SE307793B true SE307793B (sl) 1969-01-20

Family

ID=10081982

Family Applications (1)

Application Number Title Priority Date Filing Date
SE4001/65A SE307793B (sl) 1964-04-22 1965-03-27

Country Status (9)

Country Link
US (1) US3399192A (sl)
BE (1) BE662817A (sl)
CH (1) CH454160A (sl)
DE (1) DE1620262C3 (sl)
ES (2) ES312091A1 (sl)
FR (2) FR1441575A (sl)
GB (1) GB1100281A (sl)
NL (2) NL6504602A (sl)
SE (1) SE307793B (sl)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129025C (sl) * 1965-04-29
US3542729A (en) * 1968-03-19 1970-11-24 Sankyo Co Stabilization of synthetic polymers
BE790675A (fr) * 1971-10-29 1973-04-27 Science Union & Cie Nouveaux derives de l'oxa-1 diaza-3,8 spiro (4,5) decane
US4244961A (en) * 1978-10-26 1981-01-13 Syntex (U.S.A.) Inc. 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents
US4255432A (en) * 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
ES517622A0 (es) * 1982-11-23 1983-12-16 Faes Procedimiento de preparacion de un nuevo espirodecano.
YU150489A (sh) * 1989-08-10 1992-12-21 W.L. Gore & Co. Gmbh. Uređaj za ispitivanje odevnih predmeta na nepromočivost
HU204054B (en) * 1989-08-10 1991-11-28 Richter Gedeon Vegyeszet Process for producing new 1-oxa-2-oxo-8-azaspiro(4,5)decane derivatives and pharmaceutical compositions comprising same
FR2666583B1 (fr) * 1990-09-06 1994-09-09 Adir Nouveaux derives du spiro [4.5] decane, leur procede de preparation et leurs compositions pharmaceutiques les renfermant.
FR2734265B1 (fr) * 1995-05-17 1997-06-13 Adir Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
JP2004517919A (ja) * 2001-01-26 2004-06-17 シェーリング　コーポレイション 血管状態の処置のための心臓血管薬剤とステロール吸収インヒビターとの組み合わせ
EP1671650A1 (en) * 2001-01-26 2006-06-21 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
CZ309209B6 (cs) * 2001-01-26 2022-05-25 Schering Corporation Farmaceutický prostředek
EP1353694B1 (en) * 2001-01-26 2007-12-19 Schering Corporation Combinations of ezetimibe with aspirine for treating vascular conditions
AU2002241956A1 (en) * 2001-01-26 2002-08-06 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
TWI337076B (en) * 2001-01-26 2011-02-11 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
CA2447884A1 (en) * 2001-05-25 2002-12-05 Schering Corporation Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
DE10130020A1 (de) * 2001-06-25 2003-12-04 Gruenenthal Gmbh Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
DE10146275A1 (de) 2001-09-18 2003-04-24 Gruenenthal Gmbh Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
US7132415B2 (en) * 2001-09-21 2006-11-07 Schering Corporation Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
PT1427409E (pt) * 2001-09-21 2008-11-27 Schering Corp Métodos para tratar ou para impedir a inflamação vascular utilizando inibidor(es) de absorção de esteróis
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
AU2003250483A1 (en) 2002-08-19 2004-03-11 Pfizer Products Inc. Combination therapy for hyperproliferative diseases
US20040092499A1 (en) * 2002-11-06 2004-05-13 Schering Corporation Methods and therapeutic combinations for the treatment of autoimmune disorders
CN100439361C (zh) 2003-03-07 2008-12-03 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7192944B2 (en) * 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ATE418551T1 (de) 2003-03-07 2009-01-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
WO2005046797A2 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
CA2554671A1 (en) 2004-02-10 2005-08-18 F.Hoffmann-La Roche Ag Chemokine ccr5 receptor modulators
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
BRPI0809646A2 (pt) * 2007-03-29 2014-09-23 Hoffmann La Roche Compostod antivirais heterocíclicos
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CN102766147B (zh) * 2012-08-03 2015-07-15 无锡药兴医药科技有限公司 一种芬司匹利及其氢卤酸盐的制备方法
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
AU2014255381A1 (en) 2013-04-17 2015-10-08 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
EP4424697A2 (en) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
GB201416346D0 (en) * 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3193559A (en) * 1965-07-06 New derivatives of z-oxazolidinones
US2437388A (en) * 1948-03-09 Z-oxazolidone compounds and proc
US2500714A (en) * 1944-10-30 1950-03-14 Abbott Lab 4-phenyl-1-alkyl isonipecotic acid lactones
US3054794A (en) * 1958-01-17 1962-09-18 Us Vitamin Pharm Corp Process for preparing 3-(aminoalkyl)-oxazolidine-2, 4-diones
GB974134A (en) * 1963-03-28 1964-11-04 Science Union Et Compagnie Soc Oxazolidinone derivatives

Also Published As

Publication number Publication date
DE1620262B2 (de) 1979-10-11
ES361975A2 (es) 1971-01-16
CH454160A (fr) 1968-04-15
NL127065C (sl)
NL6504602A (sl) 1965-10-25
BE662817A (sl) 1965-10-21
DE1620262A1 (de) 1972-03-23
FR4463M (sl) 1966-09-26
FR1441575A (fr) 1966-06-10
US3399192A (en) 1968-08-27
GB1100281A (en) 1968-01-24
ES312091A1 (es) 1965-10-01
DE1620262C3 (de) 1980-07-03

Similar Documents

Publication Publication Date Title
FR4463M (sl)
BE671689A (sl)
BE637777A (sl)
BE432268A (sl)
BE47396A (sl)
BE483969A (sl)
BE507097A (sl)
BE642212A (sl)
BE518974A (sl)
BE642243A (sl)
BE554195A (sl)
BE564626A (sl)
BE584699A (sl)
BE603534A (sl)
BE660701A (sl)
BE610935A (sl)
BE660449A (sl)
BE660206A (sl)
BE642104A (sl)
BE628611A (sl)
BE613833A (sl)
BE660016A (sl)
BE621510A (sl)
BE658977A (sl)
BE629793A (sl)